HK1251512A1 - 靶向蛋白造影劑、其製備方法及用途 - Google Patents
靶向蛋白造影劑、其製備方法及用途Info
- Publication number
- HK1251512A1 HK1251512A1 HK18111163.8A HK18111163A HK1251512A1 HK 1251512 A1 HK1251512 A1 HK 1251512A1 HK 18111163 A HK18111163 A HK 18111163A HK 1251512 A1 HK1251512 A1 HK 1251512A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- making
- methods
- contrast agents
- targeted protein
- protein contrast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G99/00—Subject matter not provided for in other groups of this subclass
- C01G99/006—Compounds containing, besides a metal not provided for elsewhere in this subclass, two or more other elements other than oxygen or hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562159685P | 2015-05-11 | 2015-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251512A1 true HK1251512A1 (zh) | 2019-02-01 |
Family
ID=57249507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18111163.8A HK1251512A1 (zh) | 2015-05-11 | 2018-08-30 | 靶向蛋白造影劑、其製備方法及用途 |
Country Status (6)
Country | Link |
---|---|
US (4) | US10814020B2 (zh) |
EP (1) | EP3295175A4 (zh) |
CN (2) | CN118576733A (zh) |
CA (1) | CA2985075A1 (zh) |
HK (1) | HK1251512A1 (zh) |
WO (1) | WO2016183223A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118576733A (zh) * | 2015-05-11 | 2024-09-03 | 佐治亚州立大学研究基金会公司 | 靶向蛋白造影剂、其制备方法及用途 |
CN107952084A (zh) * | 2017-12-21 | 2018-04-24 | 同济大学 | 一种以人体内源性蛋白为螯合剂的磁共振造影剂及其制备 |
WO2020030954A1 (en) * | 2018-08-09 | 2020-02-13 | Integrative Medicine Clinic, Sia | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer |
US11078255B2 (en) * | 2018-08-24 | 2021-08-03 | Symthera Canada Ltd. | Ca2+ regulated binding agents |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1171152A4 (en) | 2000-02-03 | 2002-09-25 | Univ Jefferson | CXCR4 vMIP-II PEPTIDE ANTAGONISTS |
US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
DE102004061348B4 (de) * | 2004-12-20 | 2009-03-12 | Siemens Ag | Verfahren zur Auswahl eines geeigneten Kontrastmittels |
US8173105B2 (en) * | 2005-07-13 | 2012-05-08 | Georgia State University Research Foundation | Contrast agents and methods for preparing contrast agents |
CN101304767A (zh) * | 2005-09-09 | 2008-11-12 | 佐治亚州立大学研究基金会 | 靶向显像剂及显像剂靶向定位的方法 |
US8258256B2 (en) | 2006-01-05 | 2012-09-04 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
CA2668457C (en) * | 2006-11-02 | 2016-10-04 | Veridex, Llc | Imaging of activated vascular endothelium using immunomagnetic mri contrast agents |
AU2009223235B2 (en) * | 2008-03-14 | 2014-09-11 | Merck Sharp & Dohme Corp. | Integrin targeting agents and in-vivo and in-vitro imaging methods using the same |
EP2257316B1 (en) * | 2008-04-02 | 2018-11-07 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
US9956304B2 (en) * | 2012-06-05 | 2018-05-01 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
CN118576733A (zh) * | 2015-05-11 | 2024-09-03 | 佐治亚州立大学研究基金会公司 | 靶向蛋白造影剂、其制备方法及用途 |
-
2016
- 2016-05-11 CN CN202410395852.9A patent/CN118576733A/zh active Pending
- 2016-05-11 WO PCT/US2016/031900 patent/WO2016183223A2/en active Application Filing
- 2016-05-11 CN CN201680040650.6A patent/CN107850590A/zh active Pending
- 2016-05-11 CA CA2985075A patent/CA2985075A1/en active Pending
- 2016-05-11 EP EP16793465.2A patent/EP3295175A4/en active Pending
- 2016-05-11 US US15/572,863 patent/US10814020B2/en active Active
-
2018
- 2018-08-30 HK HK18111163.8A patent/HK1251512A1/zh unknown
-
2020
- 2020-09-09 US US17/015,571 patent/US11419954B2/en active Active
- 2020-09-09 US US17/015,633 patent/US11426471B2/en active Active
-
2022
- 2022-08-11 US US17/819,180 patent/US20230057249A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230057249A1 (en) | 2023-02-23 |
WO2016183223A3 (en) | 2016-12-29 |
CN107850590A (zh) | 2018-03-27 |
US20200397925A1 (en) | 2020-12-24 |
US11419954B2 (en) | 2022-08-23 |
US20180280544A1 (en) | 2018-10-04 |
EP3295175A4 (en) | 2018-12-26 |
EP3295175A2 (en) | 2018-03-21 |
US10814020B2 (en) | 2020-10-27 |
CN118576733A (zh) | 2024-09-03 |
US20210038746A1 (en) | 2021-02-11 |
US11426471B2 (en) | 2022-08-30 |
WO2016183223A2 (en) | 2016-11-17 |
CA2985075A1 (en) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249058A1 (zh) | 用於增强靶向蛋白質降解的化合物和方法 | |
ZA201907054B (en) | Anti-tau antibodies and methods of use | |
HK1250036A1 (zh) | 抗cd 166抗體,可活化抗cd 166抗體及其使用方法 | |
HK1250037A1 (zh) | 抗-itga3抗體、可活化的抗-itga3抗體、及其使用方法 | |
HK1249445A1 (zh) | 抗分揀蛋白抗體和其使用方法 | |
HK1252698A1 (zh) | 抗siglec-9抗體及其使用方法 | |
IL259495A (en) | Antibodies and methods for using them | |
IL268346A (en) | Targeted chimeric proteins and their uses | |
IL254458A0 (en) | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies and methods of using them | |
HK1252696A1 (zh) | 抗siglec-7抗體及其使用方法 | |
GB201512203D0 (en) | Agents,uses and methods | |
IL270793A (en) | Anti-HTRA1 antibodies and methods of using them | |
HK1247091A1 (zh) | 治療抗體及其用途 | |
GB201512215D0 (en) | Agents,uses and methods | |
HK1251512A1 (zh) | 靶向蛋白造影劑、其製備方法及用途 | |
IL267589A (en) | adam9 binding molecules and methods for their use | |
GB201518375D0 (en) | Agents,uses and methods | |
GB201512211D0 (en) | Agents, uses and methods | |
GB201512216D0 (en) | Agents uses and methods |